Clinical Trials Logo

HIV Infections clinical trials

View clinical trials related to HIV Infections.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03763942 Not yet recruiting - HIV Infections Clinical Trials

HealthMindr App to Increase Pre-exposure Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex With Men (MSM)

Start date: January 2019
Phase: N/A
Study type: Interventional

This study is a randomized controlled clinical trial of a theoretically based mobile app, HealthMindr, to increase pre-exposure prophylaxis (PrEP) uptake among men who have sex with men (MSM) to prevent human immunodeficiency virus (HIV). Participants in the intervention arm will receive access to the HealthMindr app, with information about PrEP and other HIV prevention methods in addition to provider locators. Participants randomized to the control arm will receive standard of care. The primary aim for this study is to assess PrEP uptake in the intervention arm compared to the control arm.

NCT ID: NCT03760458 Not yet recruiting - HIV Infections Clinical Trials

The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

Start date: February 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to examine the pharmacokinetics, safety, and tolerability of abacavir/dolutegravir/lamivudine dispersible and immediate release tablets in HIV-1-infected children less than 12 years of age.

NCT ID: NCT03753867 Not yet recruiting - HIV Infections Clinical Trials

RA Effect on Cell Surface Molecules in Vivo

Start date: January 7, 2019
Phase: Phase 1
Study type: Interventional

This study will follow a group of healthy male participants for about 18 weeks to see the effect of taking Acitretin on their immune cells

NCT ID: NCT03746600 Not yet recruiting - HIV/AIDS Clinical Trials

Technological Intervention for Reducing Alcohol Use Among People Living With HIV/AIDS

TRAC
Start date: January 2019
Phase: N/A
Study type: Interventional

While advances in medication have led to greatly improved outcomes for people living with HIV/AIDS, less than one-third of all people living with the disease are adherent enough to their medication to achieve viral suppression. Alcohol consumption has been shown to have a significant effect on HIV medication adherence, so the proposed research will aim to reduce alcohol use among people living with HIV/AIDS through a technology-driven intervention. This eight-session intervention will be delivered using a combination of videoconferencing, smart phones, and Bluetooth-enabled breathalyzers for monitoring of alcohol consumption, with an overall goal of reducing alcohol use, mitigating adherence issues, and achieving optimal prevention and treatment responses for people living with HIV/AIDS.

NCT ID: NCT03739996 Not yet recruiting - HIV Infections Clinical Trials

Long-Acting Cabotegravir Plus VRC01LS for Viral Suppression in HIV-1-Infected Adults

Start date: January 31, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and antiviral activity of long-acting cabotegravir (CAB LA) plus the broadly neutralizing monoclonal antibody, VRC-HIVMAB080-00-AB (VRC01LS), in HIV-1-infected adults with suppressed plasma viremia.

NCT ID: NCT03735849 Not yet recruiting - HIV Infections Clinical Trials

Evaluating the Safety and Pharmacokinetics of VRC-HIVMAB075-00-AB (VRC07-523LS) in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants

Start date: January 15, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and pharmacokinetics of a human monoclonal antibody (VRC07-523LS) in the sera and mucosae of healthy, HIV-uninfected adults.

NCT ID: NCT03732625 Not yet recruiting - HIV Infections Clinical Trials

Neuropsiquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study

NEARQD
Start date: January 2019
Phase: Phase 4
Study type: Interventional

Open, multicenter, non randomized, single arm, pilot trial.

NCT ID: NCT03730311 Not yet recruiting - HIV Infections Clinical Trials

Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers

Start date: December 2018
Phase: Phase 1
Study type: Interventional

A randomized, placebo-controlled, once weekly dose for four weeks, double blind study in Healthy HIV-Uninfected Volunteers (6 active; 2 placebo) with 40 mg and 80 mg in parallel followed by 120 mg after DSMB approval.

NCT ID: NCT03719664 Not yet recruiting - HIV-1-infection Clinical Trials

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

ABL
Start date: November 2018
Phase: Phase 2
Study type: Interventional

The study is an adaptive, phase 2, multicenter, three-part study to establish the dosage, safety and antiviral activity of combination therapy with albuvirtide (ABT) and 3BNC117 as long-acting maintenance therapy in virologically suppressed subjects with HIV-1 infection.

NCT ID: NCT03719521 Not yet recruiting - HIV Infection Clinical Trials

Community Based Interventions to Improve HIV Outcomes in Youth: a Cluster Randomised Trial in Zimbabwe

CHIEDZA
Start date: January 2019
Phase: N/A
Study type: Interventional

A cluster randomised trial to determine the impact of an integrated community-based package of HIV services incorporating HIV testing, linkage to care and ongoing adherence support, combined with sexual and reproductive health (SRH) services and general health counselling for 16 to 24 year olds on population level HIV viral load in a high HIV prevalence setting.